Skip to main content

Table 1 Baseline characteristics of participants

From: Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis

Baseline Characteristics Coronary calcification below median (n = 25) Coronary calcification above median (n = 26) Total (N = 51) P value Missing data
Age, y (mean; SD) 54.1 (12.7) 63.2 (12.7) 58.7 (13.4) 0.014 0
Gender, male (n; %) 15 (60) 21 (80) 36 (70.6) 0.104 0
Duration of HD, d (mean; SD) 144.6 (67.8) 145.8 (55.7) 145.2 (61.3) 0.065 0
Coronary calcification score (mean; SD) 102 (164.8) 2520.9 (1563.8) 1335 (1651) <0.001 0
Calcium, mmol/L (mean; SD) 2.3 (0.2) 2.3 (0.3) 2.3 (0.2) 0.800 1
Phosphorus, mmol/L (mean; SD) 1.8 (0.4) 1.8 (0.6) 1.8 (0.5) 0.857 1
Albumin, g/L (mean; SD) 39.4 (2.9) 36.2 (5.2) 37.8 (4.5) 0.011 1
Alkaline phosphatase, U/L (mean; SD) 99.0 (51.9) 110.0 (44.5) 104.2 (48.2) 0.490 13
Glucose, mmol/L (mean; SD) 8.8 (7.2) 9.3 (6.9) 9.0 (7.0) 0.790 1
HbA1C (mean; SD) 0.07 (0.02) 0.07 (0.02) 0.07 (0.02) 0.716 28
C reactive protein, mg/L (mean; SD) 5.5 (8.2) 31.8 (46.1) 19.3 (35.7) 0.091 30
Intact PTH, pmol/L (mean; SD) 104.5 (129.0) 104.3 (83.0) 104.4 (108.8) 0.994 10
Uric acid, μmol/L (mean; SD) 380.4 (75.5) 372.8 (78.5) 376.6 (76.1) 0.750 9
URR (mean; SD) 65.4 (16.1) 66.2 (7.3) 65.8 (12.3) 0.834 2
Hemoglobin, g/L 112.76 (12.30) 119.69 (11.31) 116.29 (12.20) 0.041 0
Comorbidities
COPD (n; %) 9 (36 %) 6 (23 %) 15 (29.4) 0.311 0
Liver disease (n; %) 2 (8 %) 0 (0 %) 2 (3.9) 0.141 0
Diabetes (n; %) 13 (52 %) 18 (69 %) 31 (60.8) 0.208 0
Hypertension (n; %) 23 (92 %) 24 (92 %) 47 (92.2) 0.967 0
Systolic blood pressure, mmHg (mean; SD) 147.6 (23.2) 145.4 (22.7) 146.5 (22.8) 0.737 0
Diastolic blood pressure, mmHg (mean; SD) 78.8 (15.9) 80.2 (14.2) 79.5 (14.9) 0.742 0
Baseline Cardiovascular Disease
Myocardial infarction (n; %) 4 (16 %) 7 (27 %) 11 (21.6) 0.343 0
CABG (n; %) 2 (8 %) 3 (11 %) 5 (9.8) 0.671 0
Percutaneous coronary intervention (n; %) 1 (4 %) 5 (19 %) 6 (11.8) 0.091 0
Atrial fibrillation (n; %) 2 (8 %) 5 (19 %) 7 (13.7) 0.244 0
DVT (n; %) 5 (20 %) 0 (0 %) 5 (9.8) 0.016 0
Pulmonary embolism (n; %) 4 (16 %) 0 (0 %) 4 (7.8) 0.034 0
Cause of ESRD
 Glomerulonephritis (n; %) 11 (44 %) 2 (8 %) 13 (25.5) 0.003 0
 Polycystic kidney disease (n; %) 2 (8 %) 1 (4 %) 3 (5.9) 0.529 0
 Diabetes mellitus (n; %) 6 (24 %) 12 (46 %) 18 (35.3) 0.098 0
 Hypertension (n; %) 5 (20 %) 10 (38 %) 15 (29.4) 0.148 0
 Other (n; %) 1 (4 %) 1 (4 %) 2 (3.9) 0.977 0
Medications
Calcium carbonate (n; %) 17 (68 %) 18 69 % 35 (68.6) 0.925 0
Sevelamer (n; %) 1 (4 %) 0 (0 %) 1 (2.0) 0.303 0
Bisphosphonates (n; %) 1 (4 %) 0 (0 %) 1 (2.0) 0.303 0
Warfarin (n; %) 4 (16 %) 5 (19 %) 9 (17.6) 0.762 0
Alfacalcidol (n; %) 14 (56 %) 9 (35 %) 23 (45.1) 0.125 0
  1. HD hemodialysis, CABG coronary artery bypass grafting, DVT deep venous thrombosis, ESRD End-stage renal disease. Missing data 0-2 % with the exceptions of alkaline phosphatase (25 %), Hb:A1C ratio (55 %), C reactive protein (59 %), INR (29 %), iPTH (20 %), and uric acid (18 %)